4 found
  1.  18
    Regulating Clinical Trials in India: The Economics of Ethics.Gerard Porter - 2018 - Developing World Bioethics 18 (4):365-374.
    The relationship between the ethical standards for the governance of clinical trials and market forces can be complex and problematic. This article uses India as a case study to explore this nexus. From the mid-2000s, India became a popular destination for foreign-sponsored clinical trials. The Indian government had sought to both attract clinical trials and ensure these would be run in line with internationally accepted ethical norms. Reports of controversial medical research, however, triggered debate about the robustness and suitability of (...)
    Direct download (5 more)  
    Export citation  
    Bookmark   1 citation  
  2.  27
    Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.Tamra Lysaght, Ian H. Kerridge, Douglas Sipp, Gerard Porter & Benjamin J. Capps - 2017 - Journal of Bioethical Inquiry 14 (2):261-273.
    Cell and tissue-based products, such as autologous adult stem cells, are being prescribed by physicians across the world for diseases and illnesses that they have neither been approved for or been demonstrated as safe and effective in formal clinical trials. These doctors often form part of informal transnational networks that exploit differences and similarities in the regulatory systems across geographical contexts. In this paper, we examine the regulatory infrastructure of five geographically diverse but socio-economically comparable countries with the aim of (...)
    Direct download (2 more)  
    Export citation  
    Bookmark   1 citation  
  3.  4
    The Medical Innovation Bill: Still More Harm Than Good.Bernadette Richards, Gerard Porter, Wendy Lipworth & Tamra Lysaght - 2015 - Clinical Ethics 10 (1-2):1-4.
    The Medical Innovation Bill continues its journey through Parliament. On 23 January 2015, it was debated for the final time in the House of Lords and with one final amendment, the House moved to support the Bill, which then moved to the House of Commons on 26 January. It will be debated again on 27 February 2015. The Bill’s purpose is to encourage responsible innovation in medical treatment. Although this goal is laudable, it is argued that the Bill is unnecessary (...)
    Direct download (3 more)  
    Export citation  
    Bookmark   2 citations  
  4. Biobanks in Japan : Ethics, Guidelines and Practice.Gerard Porter - 2009 - In Margaret Sleeboom-Faulkner (ed.), Human Genetic Biobanks in Asia: Politics of Trust and Scientific Advancement. Routledge.
    Export citation